Sajdeya Ruba, Jugl Sebastian, Wang Yan, Perez Juan G, Maloney Sophie, Lopez-Quintero Catalina, Goodin Amie J, Winterstein Almut G, Cook Robert L
Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, Gainesville, FL, USA.
Consortium for Medical Marijuana Clinical Outcomes Research, Gainesville, FL, USA.
Med Cannabis Cannabinoids. 2024 Jul 30;7(1):138-148. doi: 10.1159/000540593. eCollection 2024 Jan-Dec.
Medical cannabis (MC) is available upon certification for one of several qualifying conditions in Florida, USA. Previous studies suggested that some people seek cannabis for medical conditions/symptoms beyond those legally permitted. However, data remain limited on patient motives for seeking MC and their experiences around its impact on their health. We aimed to compare reported qualifying conditions for MC certification with the most frequently self-reported reasons for using MC while assessing the alignment between the two and understanding the perceived impacts of MC on self-reported conditions and symptoms.
We conducted a cross-sectional study using survey data from the Medical Marijuana and Me (M) Data Bank of individuals receiving MC in Florida, USA, in 2022. Participants were recruited via convenience sampling from nine MC clinics/clinic networks across Florida and were asked to fill out an online survey. The study measures included sociodemographic variables, self-reported health conditions, self-reported main reasons for using MC, self-reported qualifying conditions for MC certification, and self-reported perceived impact of MC on health conditions. We cross-tabulated reported qualifying conditions and reasons for MC use and reported the perceived impact per condition.
A total of 632 participants completed the survey, of whom 396 (62.66%) were female and 471 (74.53%) were non-Hispanic white. The median (IQR) age was 45 (35, 58). The most frequently reported qualifying conditions were post-traumatic stress disorder (PTSD) ( = 187, 29.59%), a condition not on the qualifying conditions list ( = 175, 27.69%), medical conditions of the same kind/comparable to those listed ( = 140, 22.15%), and chronic nonmalignant pain ( = 62, 25.63%). The top ten most frequently reported reasons for using MC were anxiety ( = 383, 60.60%), chronic pain ( = 278, 43.99%), depression ( = 252, 39.87%), PTSD ( = 220, 34.81%), headaches/migraine ( = 134, 21.20%), fibromyalgia ( = 67, 10.60%), attention-deficit hyperactivity disorder (ADHD) ( = 59, 9.34%), bipolar disorder ( = 53, 8.39%), high blood pressure ( = 41, 6.49%), and cancer ( = 18,2.85%). Of respondents, 70-90% with each qualifying condition reported it as one of the main reasons for using MC. Most respondents reported improvement of anxiety ( = 430/451, 95.34%), depression ( = 381/392, 97.20%), chronic pain ( = 305/310, 98.39%), insomnia/sleeping problems ( = 225/295, 86.44%), PTSD ( = 247/270, 91.48%), headaches/migraine ( = 172/218, 78.90%), ADHD ( = 82/123, 66.67%), bipolar disorder ( = 79/89, 88.76%), and fibromyalgia ( = 77/82, 93.90%). Most respondents were unsure/reported no change in blood pressure ( = 93/162, 57.41%). A small percentage reported perceived worsening impacts on their conditions.
Qualifying conditions and self-reported reasons for using MC aligned for most respondents. Yet, a notable proportion of respondents sought MC for broader treatment effects beyond those delineated by the officially recognized qualifying conditions in Florida, USA. Most patients perceived positive effects, including those with limited available evidence on efficacy.
在美国佛罗里达州,经认证符合几种限定条件之一即可使用医用大麻(MC)。先前的研究表明,一些人寻求大麻用于超出法律允许范围的医疗状况/症状。然而,关于患者寻求医用大麻的动机及其对健康影响的体验的数据仍然有限。我们旨在比较报告的医用大麻认证限定条件与最常自我报告的使用医用大麻的原因,同时评估两者之间的一致性,并了解医用大麻对自我报告的状况和症状的感知影响。
我们使用2022年美国佛罗里达州接受医用大麻治疗的个人的“医用大麻与我(M)数据库”的调查数据进行了一项横断面研究。通过便利抽样从佛罗里达州的九个医用大麻诊所/诊所网络招募参与者,并要求他们填写在线调查问卷。研究指标包括社会人口统计学变量、自我报告的健康状况、自我报告的使用医用大麻的主要原因、自我报告的医用大麻认证限定条件以及自我报告的医用大麻对健康状况的感知影响。我们对报告的限定条件和使用医用大麻的原因进行了交叉制表,并报告了每种状况的感知影响。
共有632名参与者完成了调查,其中396名(62.66%)为女性,471名(74.53%)为非西班牙裔白人。年龄中位数(四分位间距)为45岁(35,58)。最常报告的限定条件是创伤后应激障碍(PTSD)(n = 187,29.59%)、不在限定条件列表中的一种状况(n = 175,27.69%)、与所列同类/可比的医疗状况(n = 140,22.15%)以及慢性非恶性疼痛(n = 62,9.87%)。报告的使用医用大麻的十大最常见原因是焦虑(n = 383,60.60%)、慢性疼痛(n = 278,43.99%)、抑郁(n = 252,39.87%)、创伤后应激障碍(n = 220,34.81%)、头痛/偏头痛(n = 134,21.20%)、纤维肌痛(n = 67,10.60%)、注意力缺陷多动障碍(ADHD)(n = 59,9.34%)、双相情感障碍(n = 53,8.39%)、高血压(n = 41,6.49%)和癌症(n = 18,2.85%)。在每个限定条件的受访者中,70 - 90%将其报告为使用医用大麻的主要原因之一。大多数受访者报告焦虑(n = 430/451,95.34%)、抑郁(n = 381/392,97.20%)、慢性疼痛(n = 305/310,98.39%)、失眠/睡眠问题(n = 225/295,86.44%)、创伤后应激障碍(n = 247/270,91.48%)、头痛/偏头痛(n = 172/218,78.90%)、注意力缺陷多动障碍(n = 82/123,66.67%)、双相情感障碍(n = 79/89,88.76%)和纤维肌痛(n = 77/82,93.90%)有所改善。大多数受访者不确定/报告血压无变化(n = 93/